openPR Logo
Press release

Kaposi Sarcoma Market Research Report | Market Growth Analysis 2024

09-15-2017 05:03 PM CET | Health & Medicine

Press release from: Transparency Market Research

Kaposi Sarcoma Market Research Report | Market Growth Analysis

The Global Kaposi Sarcoma (KS) Market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of several major drugs.

Partnerships, acquisitions, and collaborations with other leading companies for the development of newer products with improved efficacy are part of the growth strategies adopted by a number of players in the Kaposi sarcoma market. For instance, F. Hoffmann-La Roche Ltd launched a new Global Access Program in September 2014 in partnership with the Joint United Nations Program on HIV/AIDS, the President’s Emergency Plan for AIDS Relief, the Clinton Health Access Initiative, and the Global Fund. The program was centered on HIV viral load testing.

High Incidence of HIV/AIDS, Organ Transplants Driving Growth of KS Market

Increased organ transplant procedures are a leading factor driving the Kaposi sarcoma market since the incidence of the cancer is high among patients who have undergone an organ transplant. “Organ transplant patients are given immunosuppressive agents to prevent their body from rejecting the graft. This makes them highly susceptible to Kaposi sarcoma associated herpesvirus (KSHV) infection,” the author of the study explains. The long term use of these agents increases the rate of risk of these patients by more than 100 times compared to the general population.

The high incidence of HIV/AIDS associated Kaposi sarcoma is one of the major factors driving the adoption of HAART therapy, which subsequently fuels the overall KS market.

Request to download and view full ToC -

http://www.transparencymarketresearch.com/report-toc/3354

High Cost of Treatment a Major Drawback

The cost of cancer drugs used for the treatment of Kaposi sarcoma has been on the rise in the past few years, making it difficult for patients to seek treatment. This is a major concern for both the patients and the payers. “The prices of patented drugs have increased by over five times in the past few years in the U.S. and continue to rise,” the TMR analyst comments. For instance, prices of major drugs used for the treatment of KS, such as liposomal doxorubicin, liposomal daunorubicin, or paclitaxel in combination with HAART, have been increasing significantly, making these unaffordable for middle and lower income groups.

Request to view Sample Report -

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3354

Slow but Steady Growth in Store for Kaposi Sarcoma Market

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.

By type of treatment, HAART led the overall Kaposi sarcoma market in terms of revenue, with chemotherapy and immunotherapy poised to register the highest growth rate over the coming years. In terms of region, the global Kaposi sarcoma market was led by North America in 2015 and the MEA region will record the fastest growth by 2024.

Kaposi Sarcoma Market Report is available @ US$ 5795

http://www.transparencymarketresearch.com/checkout.php?rep_id=3354<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Kaposi Sarcoma Market Research Report | Market Growth Analysis 2024 here

News-ID: 720864 • Views: 223

More Releases from Transparency Market Research

Global Waste to Energy Market is Presumed to be Valued at US$ 32 Bn by 2026
Overview TMR’s report on the Waste-to-energy Technologies Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Waste-to-energy Technologies Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Waste-to-energy Technologies Market over the forecast period.
FPSO Market is Likely to Reach a Value of US$ 66 Bn by 2026
Overview TMR’s report on the FPSO Vessels and Equipments Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the FPSO Vessels and Equipments Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the FPSO Vessels and
Recycled Plastic & Plastic Waste to Oil Market Demand and Growth Analysis with F …
Overview TMR’s report on the Recycled Plastics & Plastic Waste to Oil Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Recycled Plastics & Plastic Waste to Oil Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely
Chlorinated Paraffins Market – Size will Observe Lucrative Surge by the End202 …
Overview TMR’s report on the Chlorinated Paraffin Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Chlorinated Paraffin Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Chlorinated Paraffin Market over the forecast period.

All 5 Releases


More Releases for Kaposi

Kaposi Sarcoma Treatment Market Drivers
Increasing number of patients undergoing organ transplant procedures is the leading cause for growth of the Kaposi sarcoma treatment market, as patients undergoing organ transplants are highly susceptible to this cancer. For instance, according to the National Kidney Foundation (NKF), in 2014, 17,107 kidney transplants took place in the U.S. Among which, 11,570 came from deceased donors and 5,537 came from living donors. Furthermore, increasing incidence of HIV/AIDS-associated Kaposi sarcoma
Kaposi Sarcoma Treatment Market Competitive Landscape
Kaposi sarcoma is a malignant tumor disease majorly associated with skin, mucous membranes, lymph nodes, and other organs. Kaposi sarcoma causes lesions to grow in the skin, in the mucous membranes lining the mouth, nose, and throat, lymph nodes, and other organs. Human herpesvirus-8 (HHV-8) is majorly found in the lesion of all patients suffering from Kaposi sarcoma. However, patients with weakened immune systems by Acquired Immune Deficiency Syndrome (AIDS)
Kaposi Sarcoma Market Analysis & Trends 2024
The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in
Global Kaposi Sarcoma Market Trends & Industry Forecast by 2016 - 2024
Kaposi Sarcoma Market: Snapshot Kaposi sarcoma (KS) refers to a type of cancer that develops from the cells lining blood vessels or lymph nodes. The cancer usually appears as tumors on mucosal surfaces or on the skin, but can also develop in body parts such as the digestive tract, or the lungs. The abnormal KS cells cause brown, purple, or red blotches on the skin, called lesions. The global Kaposi sarcoma market
Kaposi Sarcoma Market Research Report 2024
The global Kaposi sarcoma (KS) market is immensely consolidated and the top two players, namely Johnson & Johnson and Merck & Co. Inc. accounted for almost 50% of the overall market in 2015. The contribution of domestic players such as Sun Pharmaceutical Industries Limited is presented low. However, Transparency Market Research predicts that the contribution of these companies will increase during the forecast period owing to the patent expiry of
Kaposi Sarcoma Market: North America Leads Global Market despite Lower Incidence …
According to the U.S. Centers for Disease Control and Prevention, Kaposi sarcoma (KS) is considered to be an AIDS-defining disease, indicating that patients with KS go on to develop AIDS. The incidence of Kaposi sarcoma was reportedly high in homosexual men with HIV. The market for Kaposi sarcoma is characterized by the increasing number of domestic players playing an important role in their respective regional markets. Given the patent expiry of